Suppr超能文献

癌症中的细胞因子

Cytokines in cancer.

作者信息

Kureshi Courtney T, Dougan Stephanie K

机构信息

Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Program in Immunology, Harvard Medical School, Boston, MA 02115, USA.

Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Program in Immunology, Harvard Medical School, Boston, MA 02115, USA.

出版信息

Cancer Cell. 2025 Jan 13;43(1):15-35. doi: 10.1016/j.ccell.2024.11.011. Epub 2024 Dec 12.

Abstract

Cytokines are proteins used by immune cells to communicate with each other and with cells in their environment. The pleiotropic effects of cytokine networks are determined by which cells express cytokines and which cells express cytokine receptors, with downstream outcomes that can differ based on cell type and environmental cues. Certain cytokines, such as interferon (IFN)-γ, have been clearly linked to anti-tumor immunity, while others, such as the innate inflammatory cytokines, promote oncogenesis. Here we provide an overview of the functional roles of cytokines in the tumor microenvironment. Although we have a sophisticated understanding of cytokine networks, therapeutically targeting cytokine pathways in cancer has been challenging. We discuss current progress in cytokine blockade, cytokine-based therapies, and engineered cytokine therapeutics as emerging cancer treatments of interest.

摘要

细胞因子是免疫细胞用来相互交流以及与周围环境中的细胞进行交流的蛋白质。细胞因子网络的多效性作用取决于哪些细胞表达细胞因子以及哪些细胞表达细胞因子受体,其下游结果会因细胞类型和环境信号而异。某些细胞因子,如干扰素(IFN)-γ,已被明确与抗肿瘤免疫相关联,而其他细胞因子,如先天性炎症细胞因子,则促进肿瘤发生。在此,我们概述细胞因子在肿瘤微环境中的功能作用。尽管我们对细胞因子网络有深入的了解,但在癌症治疗中靶向细胞因子途径一直具有挑战性。我们讨论了细胞因子阻断、基于细胞因子的疗法以及工程化细胞因子疗法作为新兴的癌症治疗方法的当前进展。

相似文献

1
Cytokines in cancer.
Cancer Cell. 2025 Jan 13;43(1):15-35. doi: 10.1016/j.ccell.2024.11.011. Epub 2024 Dec 12.
2
Targeting cytokine and chemokine signaling pathways for cancer therapy.
Signal Transduct Target Ther. 2024 Jul 22;9(1):176. doi: 10.1038/s41392-024-01868-3.
3
Cancer-related inflammation.
J Clin Immunol. 2013 Jan;33 Suppl 1:S79-84. doi: 10.1007/s10875-012-9847-0. Epub 2012 Dec 9.
4
Crosstalk of Inflammatory Cytokines within the Breast Tumor Microenvironment.
Int J Mol Sci. 2023 Feb 16;24(4):4002. doi: 10.3390/ijms24044002.
5
Local administration of mRNA encoding cytokine cocktail confers potent anti-tumor immunity.
Front Immunol. 2024 Sep 3;15:1455019. doi: 10.3389/fimmu.2024.1455019. eCollection 2024.
6
IL-35 Regulates the Function of Immune Cells in Tumor Microenvironment.
Front Immunol. 2021 May 21;12:683332. doi: 10.3389/fimmu.2021.683332. eCollection 2021.
7
Rewiring the T cell-suppressive cytokine landscape of the tumor microenvironment: a new frontier for precision anti-cancer therapy.
Front Immunol. 2024 Aug 30;15:1418527. doi: 10.3389/fimmu.2024.1418527. eCollection 2024.
9
License for destruction: tumor-specific cytokine targeting.
Trends Mol Med. 2014 Jan;20(1):16-24. doi: 10.1016/j.molmed.2013.10.002. Epub 2013 Oct 26.
10
IL-21 Signaling in the Tumor Microenvironment.
Adv Exp Med Biol. 2020;1240:73-82. doi: 10.1007/978-3-030-38315-2_6.

引用本文的文献

3
Targeting cytokine and chemokine signaling pathways for enhancing chemo-sensitivity in colorectal cancer.
Cell Commun Signal. 2025 Aug 12;23(1):369. doi: 10.1186/s12964-025-02235-7.
4
Advances in the regulation of macrophage polarization by the tumor microenvironment.
Discov Oncol. 2025 Aug 6;16(1):1487. doi: 10.1007/s12672-025-03258-9.
6
Editorial: Modulation of pro-inflammatory signaling by interferons.
Front Immunol. 2025 Jul 14;16:1657424. doi: 10.3389/fimmu.2025.1657424. eCollection 2025.
7
Oxidative Stress and Inflammation: Drivers of Tumorigenesis and Therapeutic Opportunities.
Antioxidants (Basel). 2025 Jun 15;14(6):735. doi: 10.3390/antiox14060735.
8
Cancer disrupts sex hormone-inflammation relationships: Analysis of ALI in males from NHANES 2007-2018.
PLoS One. 2025 Jun 18;20(6):e0325796. doi: 10.1371/journal.pone.0325796. eCollection 2025.
9
FOLR2 macrophages in cancer: allies or enemies.
Cell Commun Signal. 2025 Jun 2;23(1):261. doi: 10.1186/s12964-025-02257-1.

本文引用的文献

1
The type 2 cytokine Fc-IL-4 revitalizes exhausted CD8 T cells against cancer.
Nature. 2024 Oct;634(8034):712-720. doi: 10.1038/s41586-024-07962-4. Epub 2024 Sep 25.
2
A CAR enhancer increases the activity and persistence of CAR T cells.
Nat Biotechnol. 2024 Jul 30. doi: 10.1038/s41587-024-02339-4.
4
Regulation of temporal cytokine production by co-stimulation receptors in TCR-T cells is lost in CAR-T cells.
Immunother Adv. 2024 Jun 19;4(1):ltae004. doi: 10.1093/immadv/ltae004. eCollection 2024.
5
Combined JAK inhibition and PD-1 immunotherapy for non-small cell lung cancer patients.
Science. 2024 Jun 21;384(6702):eadf1329. doi: 10.1126/science.adf1329.
6
JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma.
Science. 2024 Jun 21;384(6702):eade8520. doi: 10.1126/science.ade8520.
7
Janus kinase inhibitors ameliorate clinical symptoms in patients with STAT3 gain-of-function.
Immunother Adv. 2023 Nov 24;3(1):ltad027. doi: 10.1093/immadv/ltad027. eCollection 2023.
10
IL-15 Superagonist NAI in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer.
NEJM Evid. 2023 Jan;2(1):EVIDoa2200167. doi: 10.1056/EVIDoa2200167. Epub 2022 Nov 10.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验